Phylogenomic screening reveals idsA2 loss conferring nitroimidazole cross-resistance in Mycobacterium tuberculosis
Bicyclic nitroimidazoles, notably pretomanid and delamanid, represent cornerstone agents of WHO-recommended short-course BPaLM regimens for multidrug-resis